The Medical-vs-Adult-Use Allocation: Where the $10,800/Quarter Lives

If you hold both a medical and an adult-use cultivation license, the single most valuable tax decision you will make this year is how you allocate shared costs between the two. That is not a slogan. It is arithmetic, and for a boutique grow at the scale this practice serves — roughly 10,000 square feet of canopy, on the order of $600,000 in annual gross receipts — a corrected allocation method can be worth on the order of $10,800 per quarter. This is written for that operator: the dual-license cultivator who runs one building, two license types, and one very confusing tax picture.

The reason this is live right now is the reschedule I walk through in Medical Cannabis Is Now Schedule III. In short: under current law, qualifying state-licensed medical activity sits outside Internal Revenue Code Section 280E, while adult-use (recreational) cannabis remains on Schedule I and stays fully inside §280E. Confirm the current status of that change against the record before you rely on it — this area is moving weekly — but the tax consequence for a dual-license operator is unavoidable: you now run two activities with two different federal deduction rules under one roof.

Why allocation suddenly matters

Here is the part almost no one has explained. Before the reschedule, allocation between your medical and adult-use activities did not change your federal taxable income at all. Both activities were on Schedule I, both were fully subject to §280E, and §280E disallowed every deduction below cost of goods sold for both. It did not matter which bucket you dropped a cost into — the tax answer was the same either way.

After the reschedule, the bucket is everything. Costs allocated to your medical activity are now deductible; costs allocated to your adult-use activity are still trapped at COGS-only under §280E. So the more overhead you can legitimately and defensibly attribute to the medical side of the house, the larger your federal deduction — and the smaller the tax you pay on money you never actually kept. Dual-license operators have to segregate and allocate expenses between the two activities; that is not a strategy I invented, it is the direct consequence of one activity leaving §280E while the other stayed behind.

Read that carefully, though, because the word doing the work is defensible. This is a method change, not a loophole. Any allocation you take has to hold up under the same cost-accounting rules that govern every inventory-based business — §471 and the full-absorption rules of §471-11 — and it has to be applied consistently. You do not get to move a cost to the medical side because it helps and to the adult-use side because it is easier. You pick a method you can support and you live with it.

Where the $10,800 a quarter comes from

Let me show you the shape of it with a transparent, deliberately round example. It is illustrative for an operator at this scale — not a promise, and not your numbers.

Take a grow doing about $600,000 in annual gross receipts, roughly $150,000 a quarter, split across a medical and an adult-use designation. Under the old all-§280E regime, the general and administrative overhead below your COGS line — rent on space that is not pure production, salaries for people who are not on the grow line, utilities, nutrients and supplies that are not directly absorbed into the plant, compliance costs, professional fees — was disallowed in full. For an operator this size that overhead runs comfortably into six figures a year, and every dollar of it was a dollar you paid federal tax on as if it were profit.

Now split the house. If a defensible method attributes a meaningful share of that overhead to the medical activity — the activity that is now outside §280E — that share becomes deductible for the first time. Apply a combined federal effective rate in the mid-thirties to the newly deductible overhead and the tax you stop overpaying lands, for an operator at this scale, on the order of $10,800 a quarter. Change the inputs — your real overhead, your real medical-to-adult-use ratio, your real rate — and the number moves with them. That is the whole point. The figure is an illustration of the mechanism, not a guarantee of any outcome, and the only way to know your number is to run it against your books.

The mechanism is worth saying plainly one more time: this does not make your product cheaper to grow, and it does not send you a refund check. It stops you from paying tax on overhead you were always spending, on the portion of the business that federal law now treats as an ordinary trade.

The allocation methods in play

There is no single blessed formula. There is a hierarchy of methods, and the right one depends on how your operation is actually built.

• Direct tracing. The strongest position by far. A cost that is clearly and only tied to one activity — a room grown exclusively for medical, a worker who only touches adult-use flower — is traced directly, no allocation needed. Trace everything you honestly can before you allocate anything.
• Square-footage or canopy allocation. The common workhorse for cultivation, because grow space is measurable and defensible. If medical and adult-use share a facility, the canopy each activity occupies is a rational basis for splitting shared facility costs. I go deeper on why your grow-room square footage carries so much weight in a separate guide in this library.
• Revenue-ratio allocation. Each activity's revenue over total revenue. Simple, and reasonable for costs that scale with sales rather than space.
• Production-weighted allocation. By plant count or yield, where output is the honest driver of a shared cost.

Whichever you choose, two rules sit on top of all of them: the consistency requirement of §471(c), and the full-absorption costing rules of §471-11 that govern what has to land in inventory in the first place. Those are technical enough to deserve their own treatment, and I give §471(c) full-absorption costing its own guide in this library. The short version for today: you cannot cherry-pick a different method per cost to chase the best answer, and you cannot use allocation to pull into deductible overhead something that §471-11 says belongs in inventory.

The checklist

If you do nothing else this quarter, do these five things in order.

1. Segregate revenue by activity at the source. Split medical from adult-use at the POS and in Metrc, so the revenue-by-activity numbers come from your seed-to-sale system rather than a back-of-envelope estimate.
2. Trace every directly identifiable cost. Separate grow rooms, separate labor, separate supplies — anything that belongs to one activity gets assigned to it directly before you allocate a single shared dollar.
3. Pick one defensible method for the shared overhead and apply it consistently. Square footage, revenue ratio, production weight — choose the one your operation actually supports, and use the same method across the return.
4. Document the method in a written cost-allocation memo. The method is only worth what you can defend, and you defend it with workpapers — which I cover on their own in a full-absorption workpapers guide in this library. Write down what you did and why while the facts are in front of you.
5. Have the method reviewed by an EA before you file the 2026 return. And treat the 2026 transition-year timing itself as something to verify against current IRS guidance before filing — not to assume from a headline. This is the year the review pays for itself many times over.

The risk on both sides

The IRS knows allocation is the new battleground, and it is already pushing back on cannabis positions. That cuts two ways, and both ways cost you money.

An aggressive or undocumented allocation — everything shoved onto the medical side because it helps, with nothing written down to support it — is audit bait, and a disallowance brings back tax, interest, and penalties on top. But the quieter mistake is just as expensive: a lazy allocation, dumping every shared cost onto the adult-use activity out of fifteen years of §280E habit, leaves real, deductible money sitting on the table. If you have read the symptoms of a grow that is overpaying under §280E, this is the most common one. The good news is that both failures are fixable right now, before the return goes out — which is exactly why the method review belongs on this side of your filing date, not after a notice arrives.